{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:01:53Z","timestamp":1749528113266,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was partially supported by the Key Projects of Jiangsu Provincial Health Commission .","award":["K2023028"],"award-info":[{"award-number":["K2023028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02897-2","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:31:05Z","timestamp":1749465065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of secondary primary malignancies among patients with diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Peng","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2897_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006.","journal-title":"Pathology"},{"key":"2897_CR2","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102443.","journal-title":"Cancer Treat Rev"},{"key":"2897_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, et al. Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. 2022;386:351\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"key":"2897_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2021013998","volume":"139","author":"EA Hawkes","year":"2022","unstructured":"Hawkes EA, Barraclough A, Sehn LH. Limited-stage diffuse large B-cell lymphoma. Blood. 2022;139:822\u201334. https:\/\/doi.org\/10.1182\/blood.2021013998.","journal-title":"Blood"},{"key":"2897_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood. 2010;116:2040\u20135. https:\/\/doi.org\/10.1182\/blood-2010-03-276246.","journal-title":"Blood"},{"key":"2897_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","volume":"22","author":"JS de Moor","year":"2013","unstructured":"de Moor JS, et al. Cancer survivors in the united states: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561\u201370. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1356.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2897_CR7","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1080\/10428194.2020.1811862","volume":"61","author":"Y Chinen","year":"2020","unstructured":"Chinen Y, et al. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. Leuk Lymphoma. 2020;61:3378\u201386. https:\/\/doi.org\/10.1080\/10428194.2020.1811862.","journal-title":"Leuk Lymphoma"},{"key":"2897_CR8","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","volume":"28","author":"LM Morton","year":"2010","unstructured":"Morton LM, et al. Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28:4935\u201344. https:\/\/doi.org\/10.1200\/JCO.2010.29.1112.","journal-title":"J Clin Oncol"},{"key":"2897_CR9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","volume":"22","author":"M Pirani","year":"2011","unstructured":"Pirani M, et al. Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: a meta-analysis. Ann Oncol. 2011;22:1845\u201358. https:\/\/doi.org\/10.1093\/annonc\/mdq697.","journal-title":"Ann Oncol"},{"key":"2897_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjh.14638","volume":"178","author":"L Tao","year":"2017","unstructured":"Tao L, et al. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol. 2017;178:72\u201380. https:\/\/doi.org\/10.1111\/bjh.14638.","journal-title":"Br J Haematol"},{"key":"2897_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/cncr.32513","volume":"126","author":"A Major","year":"2020","unstructured":"Major A, Smith DE, Ghosh D, Rabinovitch R, Kamdar M. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. Cancer. 2020;126:189\u2013201. https:\/\/doi.org\/10.1002\/cncr.32513.","journal-title":"Cancer"},{"key":"2897_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdv616","volume":"27","author":"I Fleury","year":"2016","unstructured":"Fleury I, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27:390\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv616.","journal-title":"Ann Oncol"},{"key":"2897_CR13","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1080\/10428194.2020.1779257","volume":"61","author":"Y Neeman","year":"2020","unstructured":"Neeman Y, Perry C, Silverman B, Waintraub N, Avivi I. Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen. Leuk Lymphoma. 2020;61:2638\u201344. https:\/\/doi.org\/10.1080\/10428194.2020.1779257.","journal-title":"Leuk Lymphoma"},{"key":"2897_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/ajh.24052","volume":"90","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, et al. Survival outcomes of secondary cancers in patients with Waldenstrom macroglobulinemia: an analysis of the SEER database. Am J Hematol. 2015;90:696\u2013701. https:\/\/doi.org\/10.1002\/ajh.24052.","journal-title":"Am J Hematol"},{"key":"2897_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-023-00784-z","volume":"13","author":"L van der Straten","year":"2023","unstructured":"van der Straten L, et al. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the netherlands, 1989\u20132019. Blood Cancer J. 2023;13:15. https:\/\/doi.org\/10.1038\/s41408-023-00784-z.","journal-title":"Blood Cancer J"},{"key":"2897_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","volume":"30","author":"JD Brewer","year":"2012","unstructured":"Brewer JD, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012;30:843\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.34.9605.","journal-title":"J Clin Oncol"},{"key":"2897_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","volume":"31","author":"BM Solomon","year":"2013","unstructured":"Solomon BM, et al. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol. 2013;31:930\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.43.4449.","journal-title":"J Clin Oncol"},{"key":"2897_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/cncr.31853","volume":"125","author":"P Barth","year":"2019","unstructured":"Barth P, Castillo JJ, Olszewski AJ. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019;125:550\u20138. https:\/\/doi.org\/10.1002\/cncr.31853.","journal-title":"Cancer"},{"key":"2897_CR19","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt A, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2:e000172. https:\/\/doi.org\/10.1136\/esmoopen-2017-000172.","journal-title":"ESMO Open"},{"key":"2897_CR20","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, et al. Second Cancer risk up to 40 years after treatment for hodgkin\u2019s lymphoma. N Engl J Med. 2015;373:2499\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa1505949.","journal-title":"N Engl J Med"},{"key":"2897_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/cncr.29231","volume":"121","author":"AK Chowdhry","year":"2015","unstructured":"Chowdhry AK, et al. Second primary head and neck cancer after hodgkin lymphoma: a population-based study of 44,879 survivors of hodgkin lymphoma. Cancer. 2015;121:1436\u201345. https:\/\/doi.org\/10.1002\/cncr.29231.","journal-title":"Cancer"},{"key":"2897_CR22","doi-asserted-by":"publisher","first-page":"107042","DOI":"10.1016\/j.leukres.2023.107042","volume":"127","author":"M Miret","year":"2023","unstructured":"Miret M, et al. Incidence of second primary malignancies in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma patients in England. Leuk Res. 2023;127:107042. https:\/\/doi.org\/10.1016\/j.leukres.2023.107042.","journal-title":"Leuk Res"},{"key":"2897_CR23","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","volume":"24","author":"NY Mudie","year":"2006","unstructured":"Mudie NY, et al. Risk of second malignancy after non-Hodgkin\u2019s lymphoma: a British cohort study. J Clin Oncol. 2006;24:1568\u201374. https:\/\/doi.org\/10.1200\/JCO.2005.04.2200.","journal-title":"J Clin Oncol"},{"key":"2897_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.12918","volume":"93","author":"S Sacchi","year":"2008","unstructured":"Sacchi S, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma: a GISL cohort study. Haematologica. 2008;93:1335\u201342. https:\/\/doi.org\/10.3324\/haematol.12918.","journal-title":"Haematologica"},{"key":"2897_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2003-04-1124","volume":"103","author":"M Andre","year":"2004","unstructured":"Andre M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222\u20138. https:\/\/doi.org\/10.1182\/blood-2003-04-1124.","journal-title":"Blood"},{"key":"2897_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108\u201315. https:\/\/doi.org\/10.1002\/cncr.21971.","journal-title":"Cancer"},{"key":"2897_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jaad.2024.03.013","volume":"91","author":"L Banner","year":"2024","unstructured":"Banner L, et al. Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A surveillance, epidemiology, and end results database analysis. J Am Acad Dermatol. 2024;91:151\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.013.","journal-title":"J Am Acad Dermatol"},{"key":"2897_CR28","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.currproblcancer.2019.100502","volume":"44","author":"S Jiang","year":"2020","unstructured":"Jiang S, Zhen H, Jiang H. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis. Curr Probl Cancer. 2020;44:100502. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.100502.","journal-title":"Curr Probl Cancer"},{"key":"2897_CR29","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","volume":"23","author":"JR Brown","year":"2005","unstructured":"Brown JR, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:2208\u201314. https:\/\/doi.org\/10.1200\/JCO.2005.05.158.","journal-title":"J Clin Oncol"},{"key":"2897_CR30","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:3159\u201365. https:\/\/doi.org\/10.1200\/JCO.2007.14.1242.","journal-title":"J Clin Oncol"},{"key":"2897_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jaccao.2023.05.001","volume":"5","author":"SK Thiruvengadam","year":"2023","unstructured":"Thiruvengadam SK, Herrera AF, Rhee JW. How to treat diffuse large B-Cell lymphoma: oncologic and cardiovascular considerations. JACC CardioOncol. 2023;5:281\u201391. https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.001.","journal-title":"JACC CardioOncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:31:05Z","timestamp":1749465065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02897-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human subjects, animal experiments, or clinical trials. Therefore, clinical trial registration and ethics committee approval were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1034"}}